Minimally invasive application of botulinum toxin A in patients with idiopathic rhinitis

Head and Face Medicine

Volumn 5, Issue 1, 2009, Pages

  Rohrbach, Saskia ^a,b   Junghans, Katharina ^a   Köhler, Sibylle ^a   Laskawi, Rainer ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRANASAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RHINITIS; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PLACEBOS; RHINITIS; TREATMENT OUTCOME;

EID: 71049172581     PISSN: None     EISSN: 1746160X     Source Type: Journal    
DOI: 10.1186/1746-160X-5-18     Document Type: Article

References (26)

1. The prevalence of allergic rhinosinusitis: a review. NS Jones AS Carney A Davis, J Laryngol Otol 1998 112 11 1019 1030 10.1017/S0022215100142380 10197137
2. Idiopathic rhinitis: idiopathic or not? AS Carney NS Jones, Clin Otolaryngol Allied Sci 1996 21 3 198 202 10.1111/j.1365-2273.1996.tb01724.x 8818486
3. Persistent rhinitis - allergic or nonallergic? C Bachert, Allergy 2004 59 Suppl 76 11 15 10.1111/j.0108-1675.2004.00389.x 14984551
4. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. DP Skoner, J Allergy Clin Immunol 2001 108 1 Suppl 2 8 10.1067/mai.2001.115569 11449200
5. International Rhinitis Management Working Group. International Consensus Report on the diagnosis and management of rhinitis, Allergy 1994 49 19 Suppl 1 34
6. Neuropeptides and nasal secretion. JN Baraniuk MA Kaliner, Am J Physiol 1991 261 223 235 1928355
7. Immunohistochemical and electron microscopic studies of substance P in guinea pig nasal glands. SY Jeon Y Majima S Kawaguchi, Acta Otolaryngol Suppl (Stockh) 1993 Suppl 506 41 46 10.3109/00016489309130239
8. Distribution, chemical coding and origin of nitric oxide synthase-containing nerve fibers the guinea pig nasal mucosa. T Kondo T Inokuchi K Ohta H Annoh J Chang, J Auton Nerv Syst 2000 80 71 79 10.1016/S0165-1838(00) 00082-5 10742542
9. Neuronal nitric oxide synthase-immunoreactivity. A neuromodulating system independent of peripheral nasal gland denervation in guinea pig nasal mucosal tissue after treatment with botulinum toxin type A. S Rohrbach A Olthoff R Laskawi W Götz, ORL J Otorhinolaryngol Relat Spec 2002 64 5 330 334 12417774
10. Neuronal nitric oxide synthase immunoreactivity in the nasal mucosa of patients with idiopathic and allergic rhinitis. A Olthoff S Rohrbach M Faber W Götz R Laskawi, ORL J Otorhinolaryngol Relat Spec 2002 64 3 180 185 12037384
11. Therapeutic uses of botulinum toxin. J Jankovicz MF Brin, N Engl J Med 1991 324 1186 1194 2011163
12. Up-to-date-report of botulinum toxin type A treatment in patients with gustatory sweating (Frey's syndrome). R Laskawi C Drobik C Schoenebeck, Laryngoscope 1998 108 381 384 10.1097/00005537-199803000-00013 9504611
13. Gustatory sweating: clinical implications and etiologic aspects. R Laskawi M Ellies R Rödel C Schoenebeck, J Oral Maxillofac Surg 1999 57 642 649 10.1016/S0278-2391(99)90420-2 10368086
14. Quantitative reduction of saliva production in two ALS patients with intraglandular injections of botulinum toxin. W Beuche C Arglebe R Laskawi, Neurol Psychiatry Brain Res 2000 8 23 26
15. Botulinum toxin to reduce saliva flow: selected indications for ultrasound-guided toxin application into salivary glands. M Ellies R Laskawi S Rohrbach-Volland C Arglebe W Beuche, Laryngoscope 2002 112 1 82 86 10.1097/00005537-200201000-00015 11802043
16. The effect of botulinum toxin type A injection for intrinsic rhinitis. KS Kim SS Kim JH Yoon JW Han, J Laryngol Otol 1998 112 3 248 51 10.1017/S0022215100158281 9624373
17. Effect of botulinum toxin type A on nasal symptoms in patients with allergic rhinitis: a double-blind, placebo-controlled clinical trial. M Unal S Sevim O Dogu Y Vayisoglu A Kanik, Acta Otolaryngol 2003 123 9 1060 3 14710908
18. A comparison of the effects of botulinum toxin A and steroid injection on nasal allergy. TY Yang YG Jung YH Kim TY Jang, Otolaryngol Head Neck Surg 2008 139 3 367 371 10.1016/j.otohns.2008.06.031 18722214
19. Rhinorrhea is decreased in dogs after nasal application of botulinum toxin. CM Shaari I Sanders BL Wu HF Biller, Otolaryngol Head Neck Surg 1995 112 4 566 71 10.1016/S0194-5998(95)70212-1 7700663
20. Botulinum toxin type A induces apoptosis in nasal glands of guinea pigs. S Rohrbach A Olthoff R Laskawi B Giefer W Götz, Ann Otol Rhinol Laryngol 2001 110 11 1045 50 11713916
21. The influence of botulinum toxin type A on vasomotor rhinitis and morphological study. J Wang F Chen M Meng X Zhang Y Chen W Huang Y Wang, Lin Chuang Er Bi Yan Hou Ke Za Zhi 2003 17 11 643 5 14971193
22. Minimally invasive application of botulinum toxin type A in nasal hypersecretion. S Rohrbach R Laskawi, ORL J Otorhinolaryngol Relat Spec 2001 63 6 382 4 11713429
23. Botox-induced prostatic involution. R Doggweiler DH Zermann M Ishigooka RA Schmidt, Prostate 2001 37 1 44 50 10.1002/(SICI)1097-0045(19980915)37: 1<44::AID-PROS7>3.0.CO;2-8
24. Basic classical, peptidergic and nitrergic innervation pattern of human nasal glands - a histochemical and immunohistochemical study. S Knipping A Riederer P Agha Mir Salim HJ Holzhausen A Berghaus, Laryngorhinootologie 2001 80 12 697 703 10.1055/s-2001-19574 11793264
25. Investigate the effect of botulinum toxin type A (BTX-A) on nasal symptoms in patients with allergic rhinitis. M Unal, Acta Otolaryngol 2005 125 2 223 10.1080/00016480410016856 15880958
26. The effect of intranasal injection of botulinum toxin A on the symptoms of vasomotor rhinitis. C Ozcan Y Vayisoglu O Dogu K Gorur, Am J Otolaryngol 2006 27 5 314 318 10.1016/j.amjoto.2006.01.008 16935174